The number of people implanted with a brain-computer interface (BCI) has more than doubled since 2024, with current estimates placing the global count at approximately 150 individuals. This surge in clinical activity marks a significant acceleration for a field that has spent decades in laboratory settings, and it signals a decisive shift from theoretical promise toward practical, if still experimental, medical application. The growth is driven by a mix of well-funded private companies and longstanding academic research consortia, each pursuing distinct technical strategies for decoding neural signals.
BCI Trials Surge as Implanted Patients Double to 150
The expansion of clinical trials is not limited to a single approach or geography. Synchron, a company based in the United States and Australia, is currently testing its stent-based BCI device in North America and Australia. Unlike traditional electrode arrays that require open-brain surgery, Synchron’s device is delivered through the jugular vein to the motor cortex, a less invasive procedure that could broaden the patient population eligible for BCI therapy. Shanghai-based Neuracle has been running its own BCI trial since November 2024 and recently obtained regulatory approval to use its device outside of clinical trials, a milestone that moves the technology one step closer to commercial availability. Precision Neuroscience, co-founded by a former co-creator of Neuralink, is also conducting trials with a BCI that sits on the surface of the brain rather than penetrating the tissue, aiming to balance signal resolution with long-term safety.
These corporate efforts run alongside decades of academic research. The University of California, Davis team that worked with patient Harrell is part of BrainGate, a BCI research initiative that has been active for over twenty years. Other academic groups are exploring a spectrum of devices, ranging from fully implanted systems to minimally invasive alternatives, reflecting a field that remains open to fundamental design trade-offs.
From Point-and-Click to Speech Decoding
The technology has evolved considerably in its capabilities. For the first 17 years of the BrainGate trial, the primary focus was on what researchers call “point-and-click” communication—allowing users to control a cursor on a screen and execute a click using only brain activity. This paradigm, while groundbreaking at the time, constrained communication speed and expressiveness. In recent years, the team shifted its focus toward decoding speech directly from neural signals, according to David Brandman, the lead investigator on the trial and the neurosurgeon who implanted Harrell’s electrodes. Today, Harrell’s system uses a voice clone—the speech it generates is based on previous recordings of Harrell’s voice, creating a more natural and personal mode of communication. This pivot from cursor control to speech decoding represents one of the most meaningful advances in the BCI field, as it directly targets the restoration of a core human function.
The Experimental Reality of Brain-Computer Interfaces
Despite the encouraging growth in trial participation, BCIs remain firmly in the experimental category. Several critical questions have yet to receive definitive answers, and the data available today only hints at the technology’s eventual shape. Most implants to date have been placed in patients with spinal cord injuries, a population for whom the potential benefit is relatively well understood. However, far less is known about how these devices might serve people with other conditions, such as amyotrophic lateral sclerosis (ALS). In some cases where BCIs initially helped patients with ALS—including individuals who were completely locked in—the devices eventually stopped functioning. Researchers have not yet determined the cause of these failures, which could stem from gliosis, electrode degradation, or changes in the neural signal itself.
The only path to answering these questions is continued research and the participation of volunteers. The current cohort of approximately 150 implanted patients, while small by the standards of medical device trials, represents a meaningful data set that can begin to reveal patterns in performance, durability, and patient outcomes. The field is moving from a phase of isolated case studies into one of systematic, multi-center evaluation.
What Is the Current State of BCI Clinical Trials?
The number of people implanted with a brain-computer interface has more than doubled since 2024 to approximately 150 individuals. These trials involve multiple companies and academic research groups across North America, Australia, and China, testing devices that range from fully implanted electrode arrays to minimally invasive stent-based systems. The technology has advanced from basic cursor control to speech decoding, but BCIs remain experimental, with unanswered questions about long-term reliability and patient selection.
Geographic and Strategic Diversification
The global spread of BCI trials is noteworthy. North America and Australia host Synchron’s trials, while China’s Neuracle has moved beyond the clinical trial framework into broader use. This geographic diversification reduces regulatory dependency on any single jurisdiction and allows parallel exploration of different regulatory pathways. For professionals monitoring the industry, the divergence in regulatory strategy—China’s relatively faster approval pathway versus the FDA’s structured trial process—will shape how quickly each technology matures and reaches patients.
The technical diversity is equally important. Synchron’s endovascular approach, Precision Neuroscience’s surface array, and the traditional penetrating arrays used by BrainGate represent fundamentally different ways of interfacing with the brain. Each approach carries distinct trade-offs in signal fidelity, surgical risk, and long-term stability. The next few years of trial data will likely clarify which of these trade-offs matters most for which patient populations.
What This Means for the Field and Its Observers
For readers tracking the BCI space—whether as healthcare professionals, investors, or technologists—the current moment is one of cautious optimism. The doubling of implanted patients is not just a numerical milestone; it signals that the logistical, regulatory, and recruitment barriers that long held the field back are beginning to yield. The technology is improving, the trials are expanding, and the questions being asked are increasingly sophisticated. However, the unresolved failures in ALS patients and the unknown longevity of implanted devices serve as reminders that BCI is still a nascent medical technology, not a mature product category. The most valuable action a professional observer can take today is to follow the detailed trial results that will emerge over the next two years, particularly in speech decoding performance and device longevity. Those data points will determine whether the current surge becomes a sustained expansion or a passing peak. Subscribe to the relevant clinical trial registries and follow the publications from the BrainGate consortium and the commercial trial sponsors directly. That is where the signal will be, and it is the only reliable way to separate genuine progress from the noise that inevitably surrounds a field as ambitious as brain-computer interfacing.
